口服避孕药使用与溃疡性结肠炎进展风险:一项全国性研究
研究纳入瑞典全国2003年起诊断的6104例16-51岁女性溃疡性结肠炎患者,随访至2014年12月,评估当前口服避孕药使用与首次溃疡性结肠炎相关手术、口服激素或抗TNF治疗的关系。当前和既往使用口服避孕药均与溃疡性结肠炎相关手术风险无显著关联(当前使用aHR=0.79,95%CI 0.52-1.18;既往使用aHR=0.74,95%CI 0.46-1.18)。
要点
- 当前口服避孕药使用与溃疡性结肠炎相关手术风险无显著关联(aHR=0.79,95%CI 0.52-1.18)。
- 既往口服避孕药使用与溃疡性结肠炎相关手术风险无显著关联(aHR=0.74,95%CI 0.46-1.18)。
- 在斯德哥尔摩郡的探索性分析中,当前口服避孕药使用与接受抗TNF治疗风险无显著关联(aHR=0.83,95%CI 0.59-1.18)。
核心结论
- 在大型全国性溃疡性结肠炎注册研究中,未发现口服避孕药使用与溃疡性结肠炎进展存在关联。
- 数据提示,就手术风险及激素或抗TNF使用风险而言,口服避孕药对已确诊溃疡性结肠炎女性具有安全性。
研究设计与样本
- 基于瑞典全国患者登记处,纳入2003年1月起诊断的6104例16-51岁女性新发溃疡性结肠炎病例。
- 当前口服避孕药使用信息来自2005年7月起的处方药登记处,随访至2014年12月。
- 主要结局为首次溃疡性结肠炎相关手术,次要结局为首次口服激素处方或抗TNF使用。
- 采用含时变协变量的Cox比例风险模型估计多变量校正风险比(aHR)及95%置信区间(CI)。
主要发现
- 随访共31421人年,观察到162例溃疡性结肠炎相关手术。
- 与未使用者相比,当前使用口服避孕药与溃疡性结肠炎相关手术风险无显著关联(aHR=0.79,95%CI 0.52-1.18)。
- 与未使用者相比,既往使用口服避孕药与溃疡性结肠炎相关手术风险无显著关联(aHR=0.74,95%CI 0.46-1.18)。
- 口服避孕药类型(仅孕激素 vs 孕激素联合雌激素)、更长使用时间或更高配药次数均未显示修饰该关联(所有Ptrend>0.28)。
- 更长使用时间或更高累积口服避孕药处方数与接受激素处方风险无关联(Ptrend分别为0.68和0.63)。
关键数值与推荐
- 当前口服避孕药使用与溃疡性结肠炎相关手术风险:aHR=0.79,95%CI 0.52-1.18。
- 既往口服避孕药使用与溃疡性结肠炎相关手术风险:aHR=0.74,95%CI 0.46-1.18。
- 口服避孕药类型、更长使用时间或更高配药次数与手术风险的交互作用:所有Ptrend>0.28。
- 更长使用时间或更高累积处方数与接受激素处方风险:Ptrend分别为0.68和0.63。
- 斯德哥尔摩郡探索性分析中,当前口服避孕药使用与接受抗TNF治疗风险:aHR=0.83,95%CI 0.59-1.18。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Oral contraceptive (OC) use has been consistently linked to increased risk of inflammatory bowel disease. Nonetheless, a specific role of OC in the natural history of ulcerative colitis (UC) is unknown. METHODS: We identified 6,104 incident female UC cases aged 16-51 years at diagnosis from the Swedish National Patient Register starting in January of 2003. Information on current OC use was obtained from the Prescribed Drug Register starting in July of 2005. We followed cases through December of 2014 for primary outcome defined as first UC-related surgery, and the secondary outcomes defined by recipient of the first prescription of oral steroids or anti-tumor necrosis factor (anti-TNF) use. We used Cox proportional hazard modeling with time-varying covariates to estimate multivariable-adjusted hazard ratio (aHR) and 95% confidence interval (CI). RESULTS: Over 31,421 person-years of follow up, we observed 162 cases of UC-related surgery. Compared with nonusers, current and past use of OC were not significantly associated with risk of UC-related surgery (aHR=0.79; 95% CI, 0.52-1.18; and aHR=0.74, 95% CI, 0.46-1.18, respectively). The association did not appear to be modified by type of OC use (progestin-only vs. combination of progestin and estrogen), longer duration of use, or higher number of dispensed prescriptions (All Ptrend>0.28). Similarly, longer use or higher cumulative number of OC prescriptions were not associated with increased risk of receiving a steroid prescription (Ptrend=0.68 and 0.63, respectively). In exploratory analyses restricted to Stockholm county, current OC use was not associated with increased risk of receiving anti-TNF therapy (aHR=0.83, 95% CI, 0.59-1.18). CONCLUSIONS: In a large nationwide registry of UC patients, we found no association between OC use and UC progression. Our data offer reassurance regarding the safety of OC assessed by its effect on risk of surgery and steroid or anti-TNF use in women with established UC.
引用
- Khalili H, Neovius M, Ekbom A, et al. Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. Am J Gastroenterol. 2016. PMID: 27725646. doi:10.1038/ajg.2016.464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。